OSTXASEHealthcare·Biotechnology#411 in industry

OS Therapies Incorporated

Reports in 17d· 2026-05-14

+22.1% · 90d

$1.77

+0.00 (+0.00%)

After-Hours $1.79(+0.02)

News

(1)

April 2026

Apr 2, 20263 weeks ago8-KHealthcare

OS Therapies Inc — 8-K Filing

OSTXOS Therapies Inc

# 🧾 What This Document Is This is an 8-K filing from OS Therapies Inc. (OSTX). It's a current report that companies must file with the SEC to announce major events. This specific filing includes two attached agreements that together announce one big event: **the company is raising money by selling

Read summaryView on SEC EDGAR

Key Data

Market Cap$77.2M

Open$1.79

Prev Close$1.77

Day Range$1.69 – $1.82

52W Range$1.15 – $2.57

Volume1,190,846

P/E (TTM)—

EPS$-0.98

Dividend Yield—

Beta—

Price Target$10.89(+515.1%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy4 analysts

Buy 4Hold 0Sell 0

About

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

Healthcare · Biotechnology

4 employees

ostherapies.com